[go: up one dir, main page]

PE20091452A1 - Hidantoinas sustituidas - Google Patents

Hidantoinas sustituidas

Info

Publication number
PE20091452A1
PE20091452A1 PE2008002070A PE2008002070A PE20091452A1 PE 20091452 A1 PE20091452 A1 PE 20091452A1 PE 2008002070 A PE2008002070 A PE 2008002070A PE 2008002070 A PE2008002070 A PE 2008002070A PE 20091452 A1 PE20091452 A1 PE 20091452A1
Authority
PE
Peru
Prior art keywords
phenyl
lower alkyl
cycloalkyl
diona
imidazolidine
Prior art date
Application number
PE2008002070A
Other languages
English (en)
Inventor
Shaoqing Chen
Nicholas John Silvester Huby
Norman Kong
John Anthony Moliterni
Omar Jose Morales
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20091452A1 publication Critical patent/PE20091452A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/74—Two oxygen atoms, e.g. hydantoin with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to other ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
    • C07D233/78—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

REFERIDO A UN COMPUESTO DERIVADO DE HIDANTOINA DE FORMULA I, DONDE R1 ES HALOGENO Y ALQUINILO INFERIOR, R2 ES H Y FLUOR, R3 Y R4 SON CADA UNO H, HALOGENO Y ALQUILO INFERIOR, R5 ES H, Cl, Y ALQUILO INFERIOR, R6 ES ARILO OPCIONALMENTE SUSTITUIDO, CICLOALQUILO C3-C7, -(CH2)n-CICLOALQUILO C3-C7, ENTRE OTROS, n ES 0, 1 O 2, R7 ES H Y (a), DONDE R8 ES H, ALQUILO INFERIOR, CICLOALQUILO C3-C6, ENTRE OTROS, R9 Y R10 SON CADA UNO H Y ALQUILO INFERIOR O R9 Y R10 JUNTOS FORMAN CICLOALQUILO C3-C7 Y R8 ES H. SON COMPUESTOS PREFERIDOS: (R)-5-[4-(2-HIDROXI-ETOXI)-FENIL]-3-{(S)-1-[5-(4-YODO-FENIL)-1H-IMIDAZOL-2-IL]-2-FENIL-ETIL}-IMIDAZOLIDINA-2,4-DIONA, (R)-3-{(S)-1-[5-(4-YODO-FENIL)-1H-IMIDAZOL-2-IL]-2-FENIL-ETIL}-5-PROP-2-INIL-IMIDAZOLIDINA-2,4-DIONA, (R)-5-[4-(2-HIDROXI-ETOXI)-FENIL]-3-{(S)-1-[5-(4-YODO-FENIL)-1H-IMIDAZOL-2-IL]-1-METIL-2-FENIL-ETIL}-IMIDAZOLIDINA-2,4-DIONA. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE EL COMPUESTO DE FORMULA I Y A UN PROCESO PARA OBTENERLA, DICHO COMPUESTO ES INHIBIDOR DE LA QUINASA MEK, SIENDO UTIL PARA EL TRATAMIENTO DE LA ENFERMEDAD DE ALZHEIMER, DEMENCIA, TUMORES DE MAMA, DE PULMON, DE PROSTATA, ENTRE OTROS
PE2008002070A 2007-12-20 2008-12-12 Hidantoinas sustituidas PE20091452A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1522207P 2007-12-20 2007-12-20
US10325908P 2008-10-07 2008-10-07

Publications (1)

Publication Number Publication Date
PE20091452A1 true PE20091452A1 (es) 2009-09-23

Family

ID=40380157

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008002070A PE20091452A1 (es) 2007-12-20 2008-12-12 Hidantoinas sustituidas

Country Status (15)

Country Link
US (1) US8063085B2 (es)
EP (1) EP2234982A1 (es)
JP (1) JP2011506533A (es)
KR (1) KR20100086503A (es)
CN (1) CN101896469A (es)
AR (1) AR069795A1 (es)
AU (1) AU2008341680A1 (es)
BR (1) BRPI0820696A2 (es)
CA (1) CA2707650A1 (es)
CL (1) CL2008003814A1 (es)
IL (1) IL205605A0 (es)
MX (1) MX2010006331A (es)
PE (1) PE20091452A1 (es)
TW (1) TW200932217A (es)
WO (1) WO2009080523A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011106570A1 (en) 2010-02-24 2011-09-01 Medivation Prostate Therapeutics, Inc. Processes for the synthesis of diarylthiohydantoin and diarylhydantoin compounds
CN102020651B (zh) 2010-11-02 2012-07-18 北京赛林泰医药技术有限公司 6-芳基氨基吡啶酮甲酰胺mek抑制剂
CN103342693A (zh) * 2013-07-31 2013-10-09 上海康鹏化学有限公司 反式-2-(4-卤-3-氟苯基)-5-烷基-[1,3]二氧六环的制备方法
CN104860869B (zh) * 2015-04-03 2017-11-03 北京大学 具有mek激酶抑制功能的化合物及其制备方法与应用
CN105152977B (zh) * 2015-09-28 2017-06-23 西南大学 D‑对羟基苯甘氨酸衍生物及其制备方法和应用
WO2018053517A1 (en) * 2016-09-19 2018-03-22 The Texas A&M University System Inhibitors of ldlr-pcsk9 protein-protein interaction and methods of their use
WO2025043043A2 (en) * 2023-08-24 2025-02-27 Musc Foundation For Research Development Mek1 inhibitors and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010014362A (ko) 1997-07-01 2001-02-26 로즈 암스트롱, 크리스틴 에이. 트러트웨인 4-브로모 또는 4-요오도 페닐아미노 벤즈히드록삼산유도체 및 ｍｅｋ 억제제로서의 그의 용도
KR19990012061A (ko) * 1997-07-26 1999-02-25 성재갑 파네실 전이효소 저해제로 유용한 하이덴토인 유도체
AU2001252270B2 (en) * 2000-05-03 2005-12-15 F. Hoffmann-La Roche Ag Hydantoin-containing glucokinase activators
CN1219753C (zh) 2000-07-19 2005-09-21 沃尼尔·朗伯公司 4－碘苯氨基苯氧肟酸的氧合酯
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
WO2003077914A1 (en) 2002-03-13 2003-09-25 Array Biopharma, Inc N3 alkylated benzimidazole derivatives as mek inhibitors
EP1546109A4 (en) * 2002-10-04 2005-11-09 Bristol Myers Squibb Co HYDANTOIN DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND / OR TNF-ALPHA CONVERSION ENZYME (TACE)
ES2331246T3 (es) 2003-07-24 2009-12-28 Warner-Lambert Company Llc Derivados de benzamidazol como inhibidores del mek.
ES2313389T3 (es) 2004-08-17 2009-03-01 F. Hoffmann-La Roche Ag Hidantoinas sustituidas.
TW200621766A (en) * 2004-09-17 2006-07-01 Hoffmann La Roche Substituted hydantoins
WO2006124780A2 (en) 2005-05-12 2006-11-23 Kalypsys, Inc. Ih-benzo [d] imidazole compounds as inhibitors of b-raf kinase
FR2891543A1 (fr) 2005-10-05 2007-04-06 Oreal Composes phenyl-furyl-methyl-thiazolidine-2,4-diones ou phenyl-thienyl-methyl-thiazolidine-2,4-diones ; utilisations pour stimuler ou induire la pousse des fibres keratiniques et/ou freiner leur chute ; compositions le contenant
US7612212B2 (en) * 2006-02-22 2009-11-03 Hoffmann-La Roche Inc. Substituted hydantoins

Also Published As

Publication number Publication date
AR069795A1 (es) 2010-02-17
KR20100086503A (ko) 2010-07-30
WO2009080523A1 (en) 2009-07-02
JP2011506533A (ja) 2011-03-03
IL205605A0 (en) 2010-11-30
BRPI0820696A2 (pt) 2019-09-24
CL2008003814A1 (es) 2009-10-23
CA2707650A1 (en) 2009-07-02
US20090170920A1 (en) 2009-07-02
MX2010006331A (es) 2010-07-05
US8063085B2 (en) 2011-11-22
TW200932217A (en) 2009-08-01
EP2234982A1 (en) 2010-10-06
AU2008341680A1 (en) 2009-07-02
CN101896469A (zh) 2010-11-24

Similar Documents

Publication Publication Date Title
PE20091452A1 (es) Hidantoinas sustituidas
PE20081636A1 (es) Inhibidores de antranilamida para aurora quinasa
PE20110875A1 (es) Derivados de isoindol como inhibidores de bace
PE20170664A1 (es) Agonistas del receptor de apelina(apj) y usos de los mismos
PE20120861A1 (es) Compuestos y composiciones como inhibidores de cinasa de proteina
PE20191755A1 (es) Derivados de pirazol como inhibidores de malt 1
PE20091656A1 (es) Compuestos heterociclicos como inhibidores de la cinasa raf
PE20091673A1 (es) Nuevos derivados de carbazol, inhibidores de hsp90, composiciones que los contienen y utilizacion
NZ591449A (en) Picolinamide derivatives as kinase inhibitors
PE20110894A1 (es) Derivados de pirimidin indol para el tratamiento de cancer
PE20110062A1 (es) N-(3-(3,5-dimetoxifenetil)-1h-pirazol-5-il)-4-(3,4-dimetilpiperazin-1-il)benzamida y sales del mismo
PE20061366A1 (es) Compuestos y composiciones como inhibidores de quinasa de proteina
PE20141375A1 (es) Activadores de glucoquinasa
JP2018536653A5 (es)
PE20120812A1 (es) Compuestos vinil indazolilo
PE20160521A1 (es) Inhibidores de autotaxina que comprenden un nucleo ciclico de anillo heteroaromatico-bencil-amida
AR076008A1 (es) Derivados de hidroximetil-isoxazol moduladores de receptores gaba a, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos para el tratamiento del alzheimer y otros trastornos cognitivos.
PE20081665A1 (es) Antagonistas del receptor de dopamina 2 de rapida disociacion
PE20090243A1 (es) Compuestos de imidazol sustituido como inhibidores de renina
HRP20120738T1 (hr) Inhibitori kinaza akt i p70 s6
PE20090482A1 (es) Derivados heterociclicos como antagonistas del receptor ccr2
PE20090592A1 (es) Nuevos derivados de piperazina-amida
JP2017500321A5 (es)
AR052330A1 (es) Derivados de adamantano que comprenden quinoleinas sustituidas
PE20121439A1 (es) Derivados de pirazol que modulan la estearoil-coa-desaturasa

Legal Events

Date Code Title Description
FD Application declared void or lapsed